The Pharmacovigilance Branch uses a number of post-marketing risk assessment approaches to ensure the continued safe use of health products. These include mandatory reporting from pharmaceutical manufacturers, spontaneous reporting from health professionals, literature reviews and the exchange of regulatory information with other national drug regulatory bodies.

Click here for the HSA Adverse Events Watch.